Nortel Settles

Nortel Networks Corp. (NYSE: NT), the largest North American telephone equipment maker, has announced the preliminary settlement of the securities class actions pending against the company in the S.D.N.Y. The cases are related to Nortel’s announcement of revised financial guidance during 2001 and its revision of its 2003 financial results and restatement of other prior periods.

The proposed settlement is for $2.4 billion in cash and stock. In particular, Nortel has agreed to pay $575 million in cash and issue stock equivalent to 14.5 percent of the company. Nortel also will contribute one-half of any recovery from its existing litigation against certain former officers who were terminated for cause. The agreement is conditioned on payments from existing insurance – an issue that has not yet been resolved.

Bloomberg reports that the proposed settlement is the fifth-largest securities class action settlement in U.S. history.

Leave a comment

Filed under Settlement

Cornerstone Releases Report On Settlements

Cornerstone Research has released an updated report on post-PSLRA settlements of securities class actions through December 2005. The findings include:

(1) Excluding the Enron and WorldCom settlements, the value of securities class action settlements was $3.5 billion in 2005, up from $2.9 billion in 2004.

(2) The settlement value increase is attributable to a 10% increase in the number of settlements (124 in 2005 vs. 113 in 2004), a $2.1 million increase in average settlement value ($28.5 million in 2005 vs. $26.4 million in 2004), and an increase in the number of settlements over $100 million (9 in 2005 vs. 7 in 2004).

(3) The median value of settlements increased 19% to $7.5 million in 2005.

Quote of Note (press release): “[W]hile the Cornerstone study finds a significant increase in settlement amounts in 2005, a report recently issued by the Stanford Law School Securities Class Action Clearinghouse in cooperation with Cornerstone Research found decreases in 2005 in both the number of case filings, as well as the amount of investor losses associated with case filings. Since there is a delay between case filings and case resolutions, these results suggest – along with the effects of the Dura decision – potential lower settlement values in the future.”

Leave a comment

Filed under Lies, Damn Lies, And Statistics, Settlement

The Filing Debate

The Cornerstone/Stanford report on securities class actions filings in 2005 has been the subject of press commentary, primarily focused on the “sharp decline” in cases. The New York Times has a Legal Beat column discussing the report in today’s edition.

There are two interesting questions that arise out of the report’s findings.

First, is the decline actually significant? Securities Litigation Watch has done a great job of pointing out that commentators are ignoring the actual statistical trend – perhaps because they are merely relying on the press release that accompanied the report. In the context of post-PSLRA filings (i.e., since 1996), last year’s 175 filings is entirely consistent with the normal up-and-down pattern.

Second, and perhaps more interestingly, why was there no rise in the number of securities class action filings last year given the astonishing increase in financial restatements? There were an estimated 1200 financial restatements in 2005, nearly twice as many as in 2004. Although not every financial restatement brings a lawsuit, there is little doubt that the correlation is significant. The Cornerstone/Stanford report found that 89% of securities class actions filed in 2005 alleged misrepresentations in financial documents.

The New York Times column states that restatements are becoming more commonplace and may not indicate misconduct, but then quotes some experts suggesting that the real reason for the decline in filings is a combination of the PSLRA and judicial decisions (including Dura) that have made it more difficult for investors to bring cases. One missing link, however, is the relationship between restatements and stock price declines. The announcement of a restatement that is not accompanied by a significant stock price decline is unlikely to engender a securities class action (not enough damages). So it would appear that we need at least one more piece of the statistical puzzle: how many of last year’s restatements led to a significant stock price decline?

Leave a comment

Filed under Lies, Damn Lies, And Statistics

Elliott Weiss Interview

Professor Elliott Weiss, a well-known securities law expert, is the author of a law review article (“Let the Money Do the Monitoring: How Institutional Investors Can Reduce Agency Costs in Securities Class Actions”) that was the basis for the PSLRA’s lead plaintiff provisions. In an interesting career change, Professor Weiss has joined a prominent securities class action plaintiffs’ firm. Securities Litigation Watch has an interview.

Leave a comment

Filed under All The News That's Fit To Blog

Around The Web

(1) The Boston Business Journal has an article on securities class action litigation trends. The article suggests that the recent rise in financial restatements may lead to a boom in filings.

(2) The Chicago Tribune provides a lengthy profile of Daniel Fischel, a law professor and leading expert witness in securities cases. Fischel will be testifying on behalf of Enron’s former CEO at his criminal trial.

Leave a comment

Filed under All The News That's Fit To Blog, Enron

Here At Last

It took ten years, but the U.S. Court of Appeals for the Seventh Circuit has finally issued an opinion that comprehensively interprets the PSLRA’s heightened pleading standards. In Makor Issues & Rights, Ltd. v. Tellabs, Inc., 2006 WL 172142 (7th Cir. Jan. 25, 2006) (Wood, J.), the court addressed the following issues:

(1) Pleading of all facts – Although the PLSRA requires a complaint based on information and belief to state “all facts on which that belief is formed,” courts generally have held that this requirement should not be applied literally. The Seventh Circuit agreed with the Second Circuit that the relevant question is “whether the facts alleged are sufficient to support a reasonable belief as to the misleading nature of the statement or omission.”

(2) Confidential witnesses – In accord with a number of other circuit courts, the Seventh Circuit found that plaintiffs are not required to provide the identify of their confidential sources. It is enough for plaintiffs to describe the sources with sufficient particularity to support the probability that the person would “have access to, or knowledge of, the facts underlying the allegations.”

(3) Substantive scienter standard – The Seventh Circuit found that the PSLRA did not raise the substantive scienter standard for securities fraud, which continues to be knowledge or recklessness. (Only the Ninth Circuit has reached a different conclusion.)

(4) Pleading scienter – Under the PSLRA, a plaintiff must plead sufficient facts to create a “strong inference” of scienter or the complaint shall be dismissed. The key issue has been whether motive and opportunity allegations (e.g., insider stock trading), by themselves, can meet this pleading burden. The Second and Third Circuits say yes. The Ninth and Eleventh Circuits disagree. A number of other circuit courts, however, have taken a more holistic approach and require that all of the allegations in the complaint be collectively examined to determine whether the requisite strong inference of scienter is demonstrated. The Seventh Circuit adopted this middle ground, finding that motive and opportunity allegations may be “useful indicators.”

(5) Competing inferences – Although the Sixth Circuit has found that the “strong inference” requirement creates a situation in which plaintiffs are only entitled to the most plausible of competing inferences when a court evaluates their scienter allegations, the Seventh Circuit disagreed. Instead, the Seventh Circuit stated that it “will allow the complaint to survive if it alleges facts from which, if true, a reasonable person could infer that the defendant acted with the required intent.”

(6) Group pleading for scienter – The Seventh Circuit found that the PSLRA requires a strong inference of scienter to be pled for each defendant. Accordingly, scienter allegations made against one defendant cannot be imputed to other defendants on the theory that the officers of the company acted collectively.

For all of the legal windup, the application of the law to the facts in Makor is surprisingly brief. The district court had found that the plaintiffs failed to adequately allege scienter for any of the defendants. On appeal, the Seventh Circuit held that the allegations concerning marketing, sales, and production information available to the CEO were sufficient to establish a strong inference that he acted with fraudulent intent. The CEO’s scienter could then be imputed to the company. As for the other individual defendant, the company’s Chairman, the scienter allegations appeared to be of the “must have known” variety, and he only sold 1% of his stock holdings during the class period. Accordingly, the Rule 10b-5 claim against the Chairman was dismissed.

Holding: Affirmed in part, reversed in part. (The court also evaluated whether falsity and materiality was adequately pled for all of the statements and whether the forward-looking statements were protected by the PSLRA’s safe harbor, but its holdings on these issues were not dispositive of the overall claims against any of the defendants.)

Leave a comment

Filed under Appellate Monitor

Bristol-Myers Settles (Again)

Bristol-Myers Squibb Co. (NYSE – BMY), a global pharmaceutical company headquartered in New York, has announced a preliminary agreement to settle the securities class action pending against the company in the D.N.J. The background of the case, which was set to go to trial, is discussed in this post from last August.

The settlement is for $185 million. The plaintiffs announced that it is the “largest recovery ever obtained against a pharmaceutical company in a securities fraud case involving the development of a new drug” and that Bristol-Myers has agreed to publicly disclose the clinical study design and the results of clinical trials for every drug it markets. The company, however, was less committal about the non-financial aspects of the settlement, telling the Associated Press that it “already had two Web sites where it discloses clinical trial results.”

In 2004, Bristol-Myers paid $300 million to settle a different securities class action relating to alleged financial misstatements.

Leave a comment

Filed under Settlement

Attorneys Beware

The National Law Journal has an article on the widening exposure of law firms in securities class actions. Although the Supreme Court’s prohibition on aiding and abetting liability in private securities fraud actions has generally shielded law firms, in some cases courts have found that the law firms acted as primary violators. Plaintiffs have added fuel to that fire by arguing that even if a law firm did not make (or substantially participate in) a misrepresentation to the market, it can be held liable as a primary participant in a fraudulent scheme.

1 Comment

Filed under All The News That's Fit To Blog

Put In The Claim Form

This week’s Economist has an article (subscrip. req’d.) on the failure of many investors, including institutional investors, to file claims in securities fraud settlements. The article notes that institutional investors may be “violating their fiduciary responsibilities when they do not try to get their money” and could be the subject of “class-action suits to come.” An easy prediction – especially since those suits have already been around for a year.

Quote of note: “A study by James Cox, a colleague of Mr McGovern’s at Duke, of 118 securities class-action suits between 1995 and 2002, published in the Stanford Law Review last month, concludes that 72% of institutions never claim their full share of the proceeds. Mr Cox offers several explanations: institutions’ distaste for a form of litigation that, as they see it, benefits mainly lawyers; low expected gains; and the cost and hassle of claiming.”

Leave a comment

Filed under All The News That's Fit To Blog

Dabit Argument

Early reports from today’s Supreme Court oral argument in Merrill Lynch v. Dabit (see post below) suggest that the Second Circuit may be reversed. The justices evidently were skeptical that Congress, in passing SLUSA, meant to allow holders to bring a securities class action in state court, while forcing purchasers and sellers to bring the same case in federal court. Dow Jones Newswires (via wsj.com – subscrip. req’d) and the Financial Times (via MSNBC.com) have articles, while the Wall Street Journal’s Law Blog gets a first-hand report from a law professor who attended the hearing.

Quote of note (Financial Times): “Justice Stephen Breyer said he was worried that permitting such suits in state court would allow investors to circumvent the limits imposed by federal securities laws on purchaser and seller suits. Mr. Breyer said nothing would stop them from proceeding in state court, simply by filing their suits as holders rather than sellers. Justice Ruth Bader Ginsburg asked: ‘Why would Congress with respect to this category want there to be a more plaintiff-friendly rule than it put in place for the purchaser-seller?'”

Leave a comment

Filed under Appellate Monitor